Table 4. . Updates in hepatocellular carcinoma selective internal radiation.

Study	Trial	Phase	Number of patients	Child–Pugh class	Line of therapy	Intervention	Median OS	RR (%)	Ref.
Vilgrain et al.	SARAH	III	459	A/B	Failed 2 + rounds of chemoembolization	SIRT (Y-90) vs sorafenib	8.0 vs 9.9 (months) (p = 0.179)	19.0 vs 11.6 (p = 0.042)	[50]
Pierce et al.	SIRveNIB	III	360	A/B	≤2 rounds of chemoembolization	SIRT (Y-90) vs sorafenib	8.8 vs 10.0 (months) (p = 0.203)	16.5 vs 1.7 (p < 0.001)	[51]
Meyer et al.	TACE 2	III	313	A	1	TACE + sorafenib vs TACE + placebo	631 vs 598 (days) (p = 0.57)	36 vs 31 (p-value not provided)	[53]

OS: Overall survival; RR: Response rate; SIRT: Selective internal radiation therapy; TACE: Transarterial chemoembolization.